Recently, anti-VEGF therapy has proven to be the most useful treatment method for AMD, as it has been found to inhibit angiogenesis from between one month and two months [85,90,91,92], but it has several adverse effects, such as bleeding and infection risk from intravitreal injection, the detachment of the retina, RPE tears, vitreoretinal fibrosis, etc. [123,124]. The gene discussed is VEGFA; the disease is age-related macular degeneration.